恩扎卢胺治疗转移性去势抵抗性前列腺癌的疗效分析

陈志朋; 彭意吉; 蒋涛; 郑俊; 沈文浩

doi:10.13406/j.cnki.cyxb.003312

您当前的位置：

首页 >

文章列表页 >

恩扎卢胺治疗转移性去势抵抗性前列腺癌的疗效分析

前列腺癌 | 更新时间：2025-10-21

- 恩扎卢胺治疗转移性去势抵抗性前列腺癌的疗效分析
- Efficacy of enzalutamide in treatment of metastatic castration-resistant prostate cancer
- 重庆医科大学学报 2023年48卷第8期页码：926-930
- 作者机构：
  
  陆军军医大学第一附属医院泌尿外科，重庆 400038
- 作者简介：
  
  陈志朋，Email：czp4190@163.com，研究方向：泌尿系肿瘤的研究和治疗。
  沈文浩，Email：chongqingswh@aliyun.com。
- 基金信息：
  
  重庆市自然科学基金面上资助项目(CSTB2022NSCQ-MSX0771)
- DOI：10.13406/j.cnki.cyxb.003312
  中图分类号： R737.25
- 收稿：2023-05-31，
  
  修回：2023-07-11，
  
  录用：2023-08-02，
  
  纸质出版：2023-08-28
- 稿件说明：
移动端阅览
陈志朋,彭意吉,蒋涛,等.恩扎卢胺治疗转移性去势抵抗性前列腺癌的疗效分析[J].重庆医科大学学报,2023,48(8):926-930.

Chen Zhipeng,Peng Yiji,Jiang Tao,et al.Efficacy of enzalutamide in treatment of metastatic castration-resistant prostate cancer[J].Journal of Chongqing Medical University,2023,48(8):926-930.
陈志朋,彭意吉,蒋涛,等.恩扎卢胺治疗转移性去势抵抗性前列腺癌的疗效分析[J].重庆医科大学学报,2023,48(8):926-930. DOI： 10.13406/j.cnki.cyxb.003312.

Chen Zhipeng,Peng Yiji,Jiang Tao,et al.Efficacy of enzalutamide in treatment of metastatic castration-resistant prostate cancer[J].Journal of Chongqing Medical University,2023,48(8):926-930. DOI： 10.13406/j.cnki.cyxb.003312.

摘要

目的

探讨恩扎卢胺作为转移性去势抵抗前列腺癌（metastatic castration-resistant prostate cancer，mCRPC）的一线治疗和阿比特龙耐药后的二线治疗的疗效和安全性。

方法

回顾性分析2019年12月至2023年3月陆军军医大学第一附属医院收治的26例mCRPC患者的临床资料。综合患者血清前列腺特异性抗原（prostate specific antigen，PSA）等生化指标、影像学复查结果及治疗期间随访记录，分析患者的PSA应答、PSA进展及影像学进展等情况，以及患者治疗期间的不良事件。

结果

接受恩扎卢胺治疗的mCRPC患者总计26例，其中作为mCRPC一线治疗患者13例，服用醋酸阿比特龙治疗后出现耐药从而接受恩扎卢胺作为mCRPC二线治疗的患者13例，所有患者中位随访时间为14（4，23）个月，mCRPC一线治疗患者的PSA应答率为100%（13/13），明显高于二线治疗患者[53.8%（7/13）

]

，差异有统计学意义（

=7.800，

=0.005）。mCRPC一线治疗患者中位PSA无进展生存时间和中位无影像学生存时间分别为18.6个月和20.5个月，mCRPC二线治疗患者中位PSA无进展生存时间和中位无影像学生存时间分别为17.4个月和19.5个月。恩扎卢胺治疗患者的主要不良反应为疲乏（17/26）、潮热（3/26）和药物性肝损害（1/26），患者整体

耐受性较好。

结论

mCRPC患者进行恩扎卢胺治疗后可有效获得PSA应答，延缓肿瘤进展，作为一线治疗整体效果优于作为阿比特龙耐药的二线治疗，总体药物不良反应可耐受。

Abstract

Objective

To investigate the efficacy and safety of enzalutamide as the first-line therapy for metastatic castration-resistant prostate cancer（mCRPC） and as the second-line therapy after abiraterone resistance in the real-world setting.

Methods

A retrospective analysis was performed for the clinical data of 26 patients with mCRPC who were admitted to The First Affiliated Hospital of Army Medical University from December 2019 to March 2023. Based on the biochemical parameters including serum prostate-specific antigen（PSA），imaging reexamination results，and follow-up records during treatment，the patients were analyzed in terms of PSA response，PSA progression，and radiographic progression，and adverse events during treatment were reported.

Results

A total of 26 patients with mCRPC received enzalutamide treatment，among whom 13 patients received enzalutamide as the first-line therapy for mCRPC and 13 patients who developed resistance to abiraterone acetate received enzalutamide as the second-line therapy for mCRPC. The patients had a median follow-up time of 14（4，23） months，and the patients receiving first-line therapy had a significantly higher PSA response rate than those receiving second-line therapy（100% vs. 53.8%，

=7.800，

=0.005）. The patients receiving the first-line therapy for mCRPC had a median PSA progression-free survival time of 18.6 months and a median radiographic progression-free survival time of 20.5 months，while the patients receiving the second-line therapy for mCRPC had a median PSA progression-free survival time of 17.4 months and a median radiographic progression-free survival time of 19.5 months. The main adverse reactions observed in the patients receiving enzalutamide included fatig

ue（17/26），hot flashes（3/26），and drug-induced liver injury（1/26），which had good overall tolerability in patients.

Conclusion

Enzalutamide treatment in mCRPC patients can effectively achieve PSA response and delay tumor progression. Enzalutamide as the first-line therapy has better overall efficacy than it as the second-line therapy after abiraterone resistance，with tolerable drug-related adverse events.

关键词

Keywords

references

叶定伟，朱耀 . 中国前列腺癌的流行病学概述和启示 [J ] . 中华外科杂志， 2015 ， 53 （ 4 ）： 249 - 252 .

Ye DW ， Zhu Y . Epidemiology of prostate cancer in China：an overview and clincal implication [J ] . Chinese Journal of Surgery ， 2015 ， 53 （ 4 ）： 249 - 252 .

National Comprehensive Cancer Network . NCCN guidelines version 4.2022 prostate cancer [EB/OL ] . （ 2022-05-10 ）[ 2023-05-17 ] https：//www.nccn.org/professionals/physician_gls/pdf/prostate.pdf https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf .

Cornford P ， Van Den Bergh RC ， Briers E ， et al . EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part Ⅱ—2020 update：treatment of relapsing and metastatic prostate cancer [J ] . European urology ， 2021 ， 79 （ 2 ）： 263 - 282 .

Beer TM ， Armstrong AJ ， Sternberg CN ， et al . Enzalutamide in men with chemotherapy-naive metastatic prostate cancer（mCRPC）：results of phase Ⅲ PREVAIL study [J ] . American Society of Clinical Oncology ， 2014 ， 32 （ 4 ）： LBA11 .

Beer TM ， Armstrong AJ ， Rathkopf D ， et al . Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer：extended analysis of the phase 3 PREVAIL study [J ] . European urology ， 2017 ， 71 （ 2 ）： 151 - 154 .

Huggins C ， Stevens R ， Hodges CV . Studies on prostatic cancer：Ⅱ. The effects of castration on advanced carcinoma of the prostate gland [J ] . Archives of surgery ， 1941 ， 43 （ 2 ）： 209 - 223 .

Tran C ， Ouk S ， Clegg NJ ， et al . Development of a second-generation antiandrogen for treatment of advanced prostate cancer [J ] . Science ， 2009 ， 324 （ 5928 ）： 787 - 790 .

Von Klot CA ， Kuczyk MA ， Merseburger AS . No androgen withdrawal syndrome for enzalutamide：a report of disease dynamics in the postchemotherapy setting [J ] . European Urology ， 2014 ， 65 （ 1 ）： 258 - 259 .

Chowdhury S ， Bjartell A ， Lumen N ， et al . Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer：the prostate cancer registry [J ] . Targeted oncology ， 2020 ， 15 （ 3 ）： 301 - 315 .

Sigorski D ， Wilk M ， Gawlik-Urban A ， et al . Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland [J ] . Frontiers in Oncology ， 2023 ， 13 ： 1108937 .

何　伟，何文强 . 恩扎卢胺一线治疗去势抵抗性前列腺癌 [J ] . 中华泌尿外科杂志， 2021 ， 42 （ Z2 ）： 30 - 32 .

He W ， He WQ . First-line treatment of castration-resistant prostate cancer with enzaluamine [J ] . 2021 ， 42 （ Z2 ）： 30 - 32 .

张峰波，朱熹，吉正国，等 . 恩扎卢胺治疗阿比特龙耐药的转移性去势抵抗性前列腺癌19例疗效观察 [J ] . 现代泌尿外科杂志， 2021 ， 26 （ 7 ）： 574 - 577 .

Zhang FB ， Zhu X ， Ji ZG ， et al . Outcomes of alternative Enzalutamide after abiraterone failure in metastatic castration‐resistant prostate cancer：a report of 19 real‐world cases [J ] . Journal of Modern Urology ， 2021 ， 26 （ 7 ）： 574 - 577 .

Buttigliero C ， Tucci M ， Bertaglia V ， et al . Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer [J ] . Cancer Treatment Reviews ， 2015 ， 41 （ 10 ）： 884 - 892 .

Mateo J ， Porta N ， Bianchini D ， et al . Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations（TOPARP-B）：a multicentre，open-label，randomised，phase 2 trial [J ] . The Lancet Oncology ， 2020 ， 21 （ 1 ）： 162 - 174 .

De Bono J ， Mateo J ， Fizazi K ， et al . Olaparib for metastatic castration-resistant prostate cancer [J ] . New England Journal of Medicine ， 2020 ， 382 （ 22 ）： 2091 - 2102 .

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

托伐普坦治疗低钠血症疗效及安全性的Meta分析

高尔基体蛋白73在原发性胆汁性胆管炎中的临床价值探讨

替尼泊苷动脉化疗联合贝伐珠单抗在复发高级别脑胶质瘤的临床回顾性研究

激素受体阳性乳腺癌的内分泌治疗